If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
172
results.
Updated on
27/07/2026 [08:08:00]
Results 100 to 125 of 172
Absstract of: US20260166219A1
0000 A user-wearable patch pump system for delivery of insulin or other medicament can include a pump and an attachment portion that attaches the pump to a user's body. The pump can include a drive unit and a disposable cartridge containing a medicament with the drive unit configured to cause the pump to deliver the medicament in the cartridge to the user. The attachment portion can include a retention frame configured to selectively retain the pump therein and an adhesive patch configured to be attached to the user's body. The pump can be selectively attached to the retention frame and used to deliver medicament either through a cannula to an infusion site directly beneath the retention frame or through tubing to an infusion site displaced from the retention frame.
Absstract of: US20260166227A1
0000 The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include adjusting user specific dosage parameters in response to one or more back-filled time segments associated with a diurnal time block.
Absstract of: US20260166225A1
0000 Systems, computer programs, devices, and methods that enable coordination across multiple devices of the mobile ecosystem. In one embodiment, smart glasses detect when a user is about to eat food or take a drink and capture the consumable and portion. The data is recorded in a “morsel track” for health activity analysis. Low-fidelity captures provide preliminary recognition, while higher-fidelity captures are selectively invoked for definitive classification. Machine-learning logic generates predicted metabolic responses, such as real-time glucose trends, based on the recorded events. Predicted responses may dynamically adjust the operation of continuous glucose monitors, heart-rate sensors, or other biomedical devices. In some embodiments, the system triggers a pharmaceutical dispenser, such as an insulin pump, inhaler, or transdermal patch, to provide closed-loop therapeutic intervention in real time.
Absstract of: WO2025137203A1
The present invention relates generally to systems, devices, and methods for in vivo monitoring of an analyte level. In particular, the present invention relates to sensors having saccharides or similar molecules present in glucose-oxidase containing sensing layers to improve sensor stability.
Absstract of: US20260165661A1
0000 A device for generating alerts for Hypo and Hyperglycemia Prevention from Continuous Glucose Monitoring (CGM) determines a dynamic risk based on both information of glucose level and a trend obtainable from a CGM signals. The device includes a display whose color depends on the DR (for example, red for high DR, green for low risk). When DR exceeds a certain threshold, alerts are generated to suggest the patient to pay attention to the current glucose reading and to its trend, both of which are shown on the display in numbers and symbols (e.g. an arrow with different slope or color).
Absstract of: WO2026124490A1
A blood glucose data monitoring method for a blood glucose monitoring device, and a system, relating to the technical field of continuous glucose monitoring. The method comprises: determining motion state parameters of a user on the basis of test parameters respectively corresponding to an acceleration sensor and an angular velocity sensor at the current moment, wherein the motion state parameters comprise an acceleration vector force and an angular velocity change value; determining a tilt angle value of a blood glucose monitoring device on the basis of the motion state parameters; and determining the current motion state of the user on the basis of the tilt angle value, and matching a corresponding blood glucose monitoring algorithm on the basis of the current motion state, so as to determine the current blood glucose data of the user. The technical solution can achieve accurate identification of motion states of users, so as to achieve adjustment of related blood glucose monitoring algorithms on the basis of the motion states, thereby improving the accuracy of blood glucose value monitoring for the users.
Absstract of: US20260166094A1
0000 The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.
Absstract of: WO2026123353A1
The present invention belongs to the technical field of medical devices and particularly relates to a dual closed-loop insulin delivery system, use thereof, and a medical product thereof. Disclosed is a dual closed-loop insulin delivery system, specifically comprising a continuous glucose monitoring system, a dual closed-loop control algorithm, an insulin pump, and a specific glucose-responsive insulin analog. The present invention controls blood glucose in a dual closed-loop mode and can achieve a high time-in-range and more stable, safer, and simpler blood glucose control. Moreover, no human intervention is required during the use of the system. The present invention provides a more intelligent and user-friendlier treatment scheme for diabetic patients.
Absstract of: WO2026128809A1
Provided are compositions including a cell or cells that reduce or attenuate hybrid insulin peptide (HIP) formation, for example, a cell or cells that include an insulin gene with a genetic modification in the C-peptide sequence of the insulin gene. Also provided are methods of using the cell or cell to treat autoimmune disorders, such as type 1 diabetes (T1D), and methods of treating autoimmune disorders, such as type 1 diabetes (T1D), including inhibiting or attenuating cathepsin D (CatD) activity, and identifying CatD inhibitors to treat autoimmune disorders, such as type 1 diabetes (T1D).
Absstract of: US20260166221A1
Provided herein are systems and methods for delivering medication, such as insulin, that are user-friendly, environmentally-friendly, lower cost, discreet, less prone to errors, and/or that deliver precise, repeatable doses of medication, as well as accessories for applying and managing the same. In embodiments, the system includes a wearable insulin pump having a patch-style form factor for adhesion to a user's body surface.
Absstract of: WO2026128361A1
Disclosed herein are methods of treating a subject having diabetes with a population of stem cell-derived islet cells and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety. The subject may have received an organ transplant.
Absstract of: US20260166226A1
Presented is a medicament delivery system including a controller, a wearable medication delivery device, an analyte sensor, and other devices. In an example, a receiver is operable to receive glucose measurement values from the analyte sensor. A number of devices of the medicament delivery system may include a processor operable to execute programming code and to identify anomalous readings among the received glucose measurement values. The identified anomalous reading may, for example, be based on the received glucose measurement values violating a measurement change threshold indicative of abnormal sensor behavior. The processor may be operable to, in response to identifying the anomalous reading, revert a medicament delivery setting to a default safety basal delivery setting and/or generate a notification, an inquiry, and/or an alert for presentation to a user.
Absstract of: US20260166220A1
0000 Embodiments disclosed herein are directed to an applicator for inserting a cannula into a body of the user for delivering medication from a medication infusion device to the user. Features of the applicator device provide a more reliable, secure and safe insertion process.
Absstract of: WO2026126865A1
The present disclosure pertains to a measurement module and a measurement system with which it is possible to achieve highly accurate measurement of glucose levels. This measurement module includes a plurality of sensors to be attached to a human body via electrodes. In the measurement module, a measurement unit inputs RF signals to at least any one of the sensors to measure reflected signals and transmitted signals, and on the basis of these measured signals, outputs glucose calculation information for calculating a glucose level in the human body. The present disclosure is applicable to wearable devices such as smartwatches.
Absstract of: US20260165617A1
A sensor (e.g., an analyte sensor) that may be implanted partially or fully within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a housing, a first polymer that includes analyte indicator molecules and covers at least a portion of the housing, and a second polymer that forms an interpenetrating network with the first polymer. The second polymer may prevent biological or protein interference of the sensor.
Absstract of: US20260167932A1
0000 A method for generating immuno-free and stress-resistant donor cells comprising editing PRDM1 and FOXP3 genes in T-cells and B-cells with CRISPR-Cas9 and modulating immune responses to reduce inflammation and prevent autoimmunity. Particularly, the present invention discloses a method for treating Type 1 Diabetes, comprising genetically modifying pancreatic beta cells with CRISPR-Cas9, and altering HLA expression, and upregulating immune checkpoint molecules such as PD-L1 to obtain immune-tolerant and stress-resistant pancreatic beta cells.
Absstract of: WO2026123086A1
The present invention relates to a wearable device intended for the field of healthcare, more specifically for the continuous monitoring of vital signs and for the prevention of pressure ulcers, deep vein thrombosis (DVT) and pulmonary embolism (PE) in bedridden patients or patients with reduced mobility. The device comprises a garment equipped with sensors that monitor an electrocardiogram (ECG), respiratory rate, temperature, oximetry, arterial blood pressure, blood leakage, and glucose levels. A system of anatomical air pockets automatically adjusts the pressure in critical areas of the body so as to redistribute the pressure exerted on critical points susceptible to the formation of sores and on points prone to the formation of blood clots.
Absstract of: US20260172935A1
0000 The present disclosure regards an electronic device for insulin delivery management. The electronic device includes an antenna and a processor. The processor is configured to operate in a first communication mode and then operate in a second communication mode responsive to determining that one or more communication criteria are satisfied. The first communication mode involves communicating via the antenna with first and second peripheral devices according to respective first and duty cycles. And the second communication mode involves communicating via the antenna with the first and second peripheral devices according to respective first and second adjusted duty cycles. The first and second duty cycles are different from the first and second adjusted duty cycles, respectively.
Absstract of: WO2026127632A1
A multi-organ model for type 2 diabetes according to the present invention comprises: a pancreatic model unit including pancreatic beta cells and a pancreatic tissue-derived decellularized extracellular matrix (PdECM); an adipose tissue model unit including adipocytes, macrophages, and a visceral adipose tissue-derived decellularized extracellular matrix (VadECM); and a liver model unit including hepatocytes and a liver tissue-derived decellularized extracellular matrix (LdECM).
Absstract of: WO2026127641A1
The bioink for printing a human adipose tissue-mimicking structure of the present invention comprises a porcine adipose-derived decellularized extracellular matrix, and provides a human inflammatory disease model and a human diabetes model, both comprising a human adipose tissue-mimicking structure produced by printing with the bioink for printing a human adipose tissue-mimicking structure.
Absstract of: WO2025034851A1
Exemplary embodiments may configure the glucose cost component of a cost function used in determining basal insulin delivery doses to be limited by the maximum physiological rate of glucose level change over a time period so that the cost function more accurately reflects the physical limits of change due to insulin action, As a result, the glucose cost component of the cost function may more accurately reflect the response of a user to basal insulin deliveries, resulting in better insulin control for the user. Exemplary embodiments may modify the aggressiveness of a control approach based on a current target glucose level versus a nominal target glucose level for which the control approach was designed.
Absstract of: GB2702575A
A skin contact sensor 100 for detecting a biomarker in the interstitial fluid of a user such as a subject’s glucose or hydration levels. The sensor comprises a reusable electronics part and a disposable medical patch. The medical patch comprises a substrate 40 with a plurality of electrodes 60, conductive elements 70 (like tracks) and a contact interface 80. The substrate 40 may have a support member (90, figure 4c) and the contact interface 80 may be non-integral to the substrate 40. The reusable electronics are electrically connected to the medical patch via the contact interface 80 by an electrical connector (30, figure 4c) and removably secured to the medical patch by an adhesive such as double-sided tape. Electrical contact between the electrodes 60 and patient’s skin is provided by a conductive gel which also serves as a medium into which interstitial fluid is extracted during use and can also contain enzymes to aid in target detection. Figure 1a.
Absstract of: EP4759223A1
This invention relates to medical devices, particularly a continuous glucose monitoring (CGM) device designed for the diagnosis and monitoring of metabolic diseases such as diabetes. The invention offers an innovative monitoring solution for both type 1 diabetes, which arises from insufficient insulin production, and the more common type 2 diabetes, which is associated with insulin resistance. By enabling continuous blood sugar monitoring, the invention provides a user-friendly, eco-friendly, and cost-effective solution for diabetes management. The device allows real-time monitoring of glucose levels and delivers visual, auditory, and vibrational alerts to the user. As a result, it establishes a safer, more practical, and continuous health management system for users.
Absstract of: WO2026119202A1
Provided are a variant of glucagon-like peptide-1 (GLP-1) and use thereof. It has been discovered that GLP-1 can be degraded by an insulin-degrading enzyme (IDE), and degradation sites thereof are identified. Moreover, a GLP-1 variant with enhanced stability is designed, and the cellular secretion level and stability of GLP-1 are improved by regulating the IDE.
Nº publicación: US20260157663A1 11/06/2026
Applicant:
DEXCOM INC [US]
Dexcom, Inc.
Absstract of: US20260157663A1
0000 The present invention relates generally to systems and methods for processing, transmitting, and displaying data received from continuous analyte sensor, such as a glucose sensor. In some embodiments, the continuous analyte sensor system comprises a sensor electronics module that includes power saving features. One feature includes a low power measurement circuit that can be switched between a measurement mode and a low power mode, in which charging circuitry continues to apply power to electrodes of a sensor during the low power mode. In addition, the sensor electronics module can be switched between in a low power storage mode higher power operational mode via a switch. The switch can include a reed switch or optical switch, for example. A validation routine can also be implemented to ensure an interrupt signal sent from the switch is valid. The continuous analyte sensor can be physically connected to a sensor electronics module, which is in direct wireless communication with a plurality of different display devices.
BOPI
Electronic site
